By Chris Bailey | Thursday 11 July 2019
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
A month or so ago, I noted that Reckitt Benckiser (RB.) was a 'lower £60s buy in anticipation of a share price beginning with a '7' plus some solid dividend wrap-around...and a call option on that full split potential'. The rationale for this was not just the company's range of top products (Vanish, Nurofen, Dettol, Durex, etc.) nor even just potential upcoming split or a recently announced management evolution which I think is overdue. It was also centred on the likely resolution of the company's legacy problems with its ex pharmaceutical unit Indivior (INDV)...
Already a subscriber? Click here to sign in
This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.
Search ShareProphets |
Stock market news |
Recent Comments |
Site by Everywhen